stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Revenue growth
Exelixis, Inc.'s revenue growth over the twelve months to 30 September 2026 was 9.12%, up 2.1 percentage points from fiscal 2025 (6.98%). Over the past ten years it has ranged from 2.04% (fiscal 2020) to 415.1% (fiscal 2016); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 6.98% | (11.51) |
| FY2024 | 18.5% | 4.89 |
| FY2023 | 13.6% | 1.33 |
| FY2022 | 12.3% | (33.04) |
| FY2021 | 45.3% | 43.27 |
| FY2020 | 2.04% | (11.31) |
| FY2019 | 13.4% | (75.35) |
| FY2018 | 88.7% | (47.64) |
| FY2017 | 136.3% | (278.71) |
| FY2016 | 415.1% | 367.02 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 10.2% | (0.44) |
| Jun 2026 | 10.6% | 0.66 |
| Mar 2026 | 9.97% | 4.34 |
| Dec 2025 | 5.63% | (5.16) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. compare | 240.0% |
| BBIO BridgeBio Pharma, Inc. compare | 167.3% |
| ASND Ascendis Pharma A/S compare | 126.0% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 56.2% |
| HALO Halozyme Therapeutics, Inc. compare | 45.0% |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.5% |
| EXEL Exelixis, Inc. | 9.12% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| SMMT Summit Therapeutics PLC compare | −61.0% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement